Sentiment Survey
|
|
|
|
|
|
|
|
|
|
|
|
Investment Grade:
|
|
Comments(0)
|
(0)
|
(0)
|
Ranking History
Headlines
- Avalon Pharmaceuticals Receives NASDAQ Deficiency Notice
Nov 25, 2008 02:23 PM
- Clinical Data, Inc. to Acquire Avalon Pharmaceuticals
Oct 28, 2008 08:44 AM
- Avalon Pharmaceuticals Receives Nasdaq Deficiency Notice
Sep 26, 2008 04:17 PM
- Avalon Pharmaceuticals Reports Second Quarter 2008 Results
Aug 13, 2008 10:06 AM
- Avalon Pharmaceuticals Sets Second Quarter 2008 Conference Call Date
Aug 05, 2008 09:05 AM
- Avalon Pharmaceuticals Nominates Lead Clinical Development Candidate in its Beta-catenin Pathway Inhibitor Program
Jun 26, 2008 08:04 AM
- Avalon Pharmaceuticals Reports First Quarter 2008 Results
May 07, 2008 04:27 PM
- Avalon Pharmaceuticals to Release First Quarter 2008 Results
Apr 30, 2008 08:01 AM
- Avalon Pharmaceuticals Identifies Small Molecule Inhibitors of the Aurora/Centrosome Cancer Pathway that Block PLK3 Protein Function
Apr 14, 2008 11:08 AM
- Avalon Pharmaceuticals to Present at the American Association for Cancer Research 2008 Annual Meeting
Apr 07, 2008 08:09 AM
Analyst Ratings
|
|
Share Performance
|
Period
|
AVRX
|
Compare to S&P
|
| YTD |
-90.77 %
|
-84.88 %
|
| 4 Weeks |
-21.09 %
|
-14.71 %
|
| 12 Weeks |
-41.41 %
|
-18.78 %
|
|
Financial Ratios
Earnings Performance
|
EPS Growth in Last Quarter: -6.06 %
|
|
EPS Growth in Last Year: -9.38 %
|
|
Sales Growth in Last Quarter: -9.49 %
|
|
Sales Growth in Last Quarter: -0.01 %
|
|
|
